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Abstract
This secondary analysis explored changes in protein-unbound concentrations of lopinavir and 
amprenavir when co-administered in HIV-infected subjects. Total and unbound pharmacokinetic 
parameters were calculated and compared between subjects receiving each agent alone, and co-
administration. When co-administered, unbound and total concentrations decrease. Co-
administration significantly increased lopinavir unbound clearance, while significant changes in 
fraction unbound (fu) were not detected. For amprenavir, significant increases in fu and unbound 
clearance occurred with co-administration. This demonstrates the complex nature of drug-drug 
interactions between highly protein-bound, CYP-metabolized drugs, and the need to measure 
unbound concentrations in disease states like hepatitis C, where such agents are co-administered.
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HIV protease inhibitors (PIs) are highly bound to proteins such as albumin and alpha-1-acid 
glycoprotein. They have complex metabolism and transport profiles, and high potential for 
drug-drug interactions. For example, lopinavir (LPV) is a high-extraction drug (e.g. hepatic 
clearance is the major route of drug elimination), but it becomes low-extraction when co-
administered with ritonavir due to inhibition of CYP3A-mediated clearance.1 The ester pro-
drug of amprenavir (APV), fosamprenavir (FPV), administered to improve oral absorption, 
tolerability and reduce pill burden, may be used with or without ritonavir. In either situation, 
FPV remains a high-extraction drug.2 As previously shown, when FPV or APV is co-
administered with lopinavir/ritonavir (LPV/r), decreases in total LPV area-under-the-
concentration-time-curve (AUC) from 24-48% and decreases in total APV AUC from 
53-67% are observed.3-5
The significance of changes in plasma protein binding due to drug-drug interactions is 
widely debated in the pharmacokinetics (PK) literature.6,7 According to PK theory, only 
drugs that are high-extraction and administered intravenously, or those administered orally 
that are both high-extraction and non-hepatically eliminated should exhibit changes in 
unbound drug concentrations as a result of displacement of one drug by another on plasma 
proteins, i.e. due to a change in fraction unbound (fu). Changes in the intrinsic clearance of 
unbound drug, whether due to changes in metabolism or transport, may affect the unbound 
concentrations of orally administered, low-extraction drugs or orally administered high-
extraction drugs eliminated by hepatic mechanisms, such as LPV and APV, respectively.
Here, we expand upon previously reported decreases in total drug concentrations, with the 
observed decreases in unbound concentrations due to a drug-drug interaction between FPV 
and LPV when co-administered with ritonavir in HIV-infected subjects in AIDS Clinical 
Trials Group (ACTG) protocol A5143 and its pharmacology substudy, A5147s.
Methods
Study Protocol and Sub-study Inclusion Criteria
Details regarding A5143, A5147s, and main results have been published.3,8 Briefly, 
treatment-experienced HIV-1 infected subjects were randomized 1:1:2 into 3 arms to 
compare the efficacy and PK of lopinavir/ritonavir 400/100 mg twice daily (LPV/r; Arm A), 
fosamprenavir/ritonavir 700/100 mg twice daily (FPV/r; Arm B), and the combination of 
fosamprenavir/lopinavir/ritonavir 700/400/100 mg twice daily (LPV/FPV/r; Arm C), all 
administered with tenofovir and 1-2 additional nucleoside agents. A planned PK substudy, 
A5147s, enrolled 8, 8, and 17 evaluable subjects in Arms A (LPV/r), B (FPV/r), and C 
(LPV/FPV/r), respectively; PK data from 10 additional subjects enrolled in A5143 became 
available after publication of interim A5147s analysis. Samples collected from these 43 
subjects underwent analysis for unbound concentrations of LPV and APV. Fifteen subjects 
were further excluded from this analysis due to missing concentrations at pre-specified 
sampling points for PK parameter calculations3; 9 in the LPV/FPV/r arm, 3 in the LPV/r 
arm, and 3 in the FPV/r arm. In total, twenty-eight subjects (9, 9, and 10 in Arms A, B, and 
C, respectively) had complete and evaluable PK profiles for unbound LPV and/or APV. The 
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transfer of de-identified PK and demographic data from the ACTG to the University of 
North Carolina at Chapel Hill (UNC-CH) was approved by the ACTG and the UNC-CH 
Biomedical Institutional Review Board.
Unbound Lopinavir and Amprenavir Concentrations
The analytical methods for total drug concentrations have been previously reported.3 
Unbound concentrations of LPV and APV were determined by equilibrium dialysis using 
radiolabeled standards. The system was comprised of a Harvard apparatus multi-equilibrium 
dialyzer with Macro Teflon dialysis cells (1ml) and variable speed drive unit, a Beckman 
LS3801 Liquid Scintillation Counter, and Spectra/Por®RC membranes, using Dulbecco’s 
phosphate-buffered saline as the dialysis buffer and 900 μL of sample plasma. Equilibrium 
time was 4-5 hours. For each drug, five samples of 4 different concentrations (LPV 0.0, 0.5, 
6, and 12μg/ml; APV 0.0, 0.2, 2, and 8μg/ml) were analyzed on 5 separate days. The inter-
day percent coefficient of variation (%CV) for LPV ranged from 9.9 to 12.1%. The average 
intra-day %CV for LPV ranged from 6.8% to 8.6%. The inter-day %CV for APV ranged 
from 6.4 to 9.5%. The average intra-day %CV for APV ranged from 1.8% to 6.6%. 
Recovery was 96.2% and 92.5% for LPV and APV, respectively.
Pharmacokinetic and Statistical Analyses
The area-under-the-concentration-time curve for the dosing interval (AUCtau) was 
calculated in Phoenix Win Nonlin 6.3 (Pharsight, a Certara company, St. Louis, MO), using 
the linear-up/log-down method for both total and unbound concentrations. Apparent oral 
clearance at steady state (CL/Fss) for total concentrations was calculated as dose/AUCtau. 
Unbound clearance (CL/Fss,u) was calculated for each subject by dividing estimated total 
CL/Fss by the median fraction unbound (fu) over the dosing interval for LPV and APV.9
While the study enrolled subjects with prior exposure to either LPV or APV, but not both, 
comparisons were restricted to subjects who were naïve to the drug under evaluation and 
thus eligible for randomization to either of the arms being compared (e.g. comparisons of 
LPV PK were limited to subjects who were LPV-naïve at randomization). Statistical 
comparisons of PK parameters were carried out on the natural logarithmic scale. Geometric 
mean ratio (GMR) estimates were calculated by exponentiation of the difference in means of 
log-transformed PK measurements, and 95% Wald-type confidence intervals were computed 
using unpooled variance estimates and Satterthwaite’s approximate degrees of freedom. 
Exact Wilcoxon rank-sum tests were performed. A GMR below 1 indicates a lower 
geometric mean for APV/LPV combined (Arm C). Baseline demographics between subjects 
who did and did not have available unbound concentrations were compared using 
nonparametric tests (continuous data: Wilcoxon rank-sum test; categorical data: Fisher’s 
exact test). Statistical analyses were conducted using a two-sided statistical significance 
level of 0.05, in SAS 9.3 (SAS Institute Inc., Cary, NC) or R version 3.1.2 (www.R-
project.org). Comparisons were carried out on both total and unbound parameters; results for 
the total drug parameters presented here are not expected to provide the same results as 
those previously published, as this analysis is comprised of a set of subjects that does not 
completely overlap with the previous analysis set.3
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The mean and standard deviation (mean±SD) age of the 28 subjects with evaluable unbound 
and total PK was 44±8 years. All but two subjects were male, and 50% were Caucasian non-
Hispanic. The mean±SD log10 copies/mL of viral load at enrollment was 4.61±0.66, with 
CD4+ cell counts of 211±167 cells/mm3. No subjects in Arm A or Arm B had previous 
exposure to the randomized protease inhibitor; in Arm C, 9/10 subjects were naïve to both 
drugs, with 1 subject having previous LPV exposure. No significant differences in age, sex, 
race, baseline HIV RNA concentration, baseline CD4+ count, or previous drug exposure 
were observed between the 43 subjects with available total drug PK and the 28 with total 
and unbound PK (all p-values >0.2).
Lopinavir
The median AUCtau, 12-hr concentrations (C12hr), and clearance values of total and 
unbound LPV when administered as LPV/r and LPV/APV/r (Arm A and C, respectively) 
and GMR 95% confidence intervals and p-value for their comparisons are presented in 
Table 1; concentration-time plots of total and unbound LPV, by arm, are shown in Figure 
1a. Total LPV AUCtau and C12hr were significantly lower when combined with FPV (Arm 
C) than without (Arm A; GMR for AUCtau of 0.63 (95% CI: 0.46-0.85), p = 0.019, and 
GMR of 0.47 (0.28-0.8), p = 0.019 for C12hr). This was also true for the unbound LPV PK 
parameters (GMR for AUCtau of 0.49 (0.33-0.72), p < 0.001 and 0.35 (0.18-0.65), p = 0.008 
for C12hr). Total LPV apparent oral clearance at steady state (CL/Fss) was not significantly 
different between arms (GMR of 1.34 (0.88-2.04), p = 0.14), although the median CL/F 
during co-administration (Arm C) was approximately 45% higher compared to single 
administration (Arm A). To assess potential causes of this drug-drug interaction, the 
distribution of the fraction unbound (fu) within a subject was compared across arms; for 
LPV, the fu was higher, but not significantly different between LPV alone and LPV/APV 
co-administration (median fu of 0.011 vs 0.0088, p = 0.077). However, the LPV apparent 
oral clearance (CL/Fss,u) for unbound drug concentration was significantly higher when co-
administered with APV (671 L/hr) compared to being used alone (428 L/hr, p = 0.004).
Amprenavir
The median AUCtau, 12-hr concentrations (C12hr), and clearance values of total and 
unbound APV when administered as FPV/r and LPV/APV/r (Arm B and C, respectively), 
and GMR analyses for their comparison are presented in Table 1; concentration-time plots 
of total and unbound APV, by arm, are shown in Figure 1b. As previously reported in the 
A5147s analysis, APV PK parameters were significantly lower in the LPV/FPV/r regimen 
(Arm C) than in the FPV/r regimen (Arm B; (GMR for AUCtau of 0.45 (95% CI: 0.33-0.62), 
p < 0.001; GMR for C12 of 0.41 (0.26-0.65), p = 0.002; GMR for CL/Fss of 2.11 
(1.53-2.90), p = 0.002). This was also true for the unbound APV PK parameters (GMR for 
AUCtau of 0.62 (0.39-0.97), p = 0.035 and 0.51 (0.28-0.94), p = 0.035 for C12hr). Here, for 
APV, the fu and the CL/Fss,u were both significantly higher when dosed with LPV, with a 
median fu of 0.067 and 0.079, p = 0.010 and a median CL/Fss,u of 231 and 475 L/hr, p = 
0.037 for Arm B compared to Arm C.
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These results illustrate the complex nature of drug-drug interactions between HIV PIs. For 
LPV, CL/Fss,u was significantly higher in the presence of APV, while a significant 
difference in fu was not demonstrated, suggesting induction of hepatic metabolism or 
alteration of transport mechanisms. PIs are substrates for several drug transporters,10 which 
may be altered and increase biliary elimination, increase efflux from intestinal cells, or 
decrease efflux in hepatic cells with resultant increased metabolism. Potentially, co-
administration of multiple PIs may saturate transport mechanisms, resulting in altered 
intrinsic clearance.10 For APV, when combined with LPV, alteration in CL/Fss,u was also 
observed, as well as a significantly higher fu. These observed changes CL/Fss,u are 
consistent with pharmacokinetic theory, which predicts changes in unbound concentrations 
of these orally administered high-extraction drugs when metabolism or transport are altered. 
The significant difference in fu for APV is not consistent with pharmacokinetic theory, but is 
consistent with results from ANRS 104, where APV was administered with LPV/r, rather 
than FPV here, but only unbound APV was measured.5 Other potential mechanisms that 
could explain these APV changes, such as altered absorption or a physicochemical 
interaction in the gut are less likely, given that dose separation and increased ritonavir 
dosing still results in significantly lower LPV and APV concentrations when co-
administered.11 The complex interactions between co-administered PI that affect disposition 
may partially explain this phenomenon. Despite decreased unbound concentrations, 
however, in this and other reports, IQ ratios demonstrate unbound concentrations above the 
minimum needed for virologic effect and at least partial virologic efficacy was 
achieved.4,5,12-14
Although dual PI treatment within the context of HIV infection is not a recommended 
treatment strategy, the dawn of hepatitis C virus (HCV) PIs, which share metabolism and 
transporter pathways with HIV PIs, introduce similar conundrums when treating HIV/HCV 
co-infected patients.15 Ritonavir, which has complex effects on CYP450 enzyme and drug 
transporter inhibition and induction, is also used in HCV treatment as a pharmacokinetic 
enhancer.16-18 Decreases in unbound darunavir concentrations when co-administered with 
the HCV drug telapravir in a co-infected patient have recently been reported.19 
Understanding the mechanisms behind these changes is critical to efficacious co-
administration of these drugs. Increases in unbound clearance result in lowered unbound 
concentrations, as demonstrated here, with potential detrimental outcomes depending on the 
efficacy target of the drug.6,20 therefore, studying unbound concentrations, which are the 
determinants of efficacy, is worthwhile when drugs with complex metabolic and transport 
profile, and thus, unpredictable interactions, are co-administered.
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Total and unbound lopinavir (a) and amprenavir (b) concentration-time plots, by study arm. 
Data are shown as median with interquartile range. For both graphs, Arm C is the combined 
treatment arm; Arm A is lopinavir/ritonavir alone (a); Arm B is fosamprenavir/ritonavir 
alone (b).
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